Skip to content

NeuroDerm announces the release of positive results from the Phase 3 BouNDless study evaluating ND0612 in patients with Parkinson's disease motor fluctuations

Rehovot, Israel, March 20, 2024 (ots/PRNewswire) – Data published in The Lancet Neurology show favorable efficacy of ND0612 compared to immediate-release oral levodopa/carbidopa NeuroDerm Ltd, a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced the publication of the results of the pivotal Phase 3 BouNDless study (NCT04006210) in The Lancet Neurology […]

NeuroDerm announces the release of positive results from the Phase 3 BouNDless study evaluating ND0612 in patients with Parkinson's disease motor fluctuations
author avatar
LabNews Media LLC
The Editors in Chief of labnews.ai are Marita Vollborn and Vlad Georgescu. They are bestselling authors, science writers and science journalists since 1994.More details about their writing on X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu
LabNews Media LLC

LabNews Media LLC

The Editors in Chief of labnews.ai are Marita Vollborn and Vlad Georgescu. They have been bestselling authors, science writers, and science journalists since 1994.More details about their writing at X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu